drugset / Trial / NCT00517322

Left Atrial Remodelling in Hypertension: Effects of Ramipril or Irbesartan

NCT00517322

Phase 4 Unknown 80 enrolled University of Insubria
RandomizedParallel-groupDouble-blindTreatment

Summary

Aim of the study is to compare in hypertensive patients the effect of one year therapy with ACE-inhibitor (RAMIPRIL) or angiotensin II receptor blocker (IRBESARTAN) on left atrial remodelling and diastolic function.

Timeline

Start
2007-08
Primary completion
Completion
2010-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Irbesartan Small molecule 150 mg
Subject Irbesartan Small molecule 300 mg
Subject Ramipril Small molecule 2.5 mg
Subject Ramipril Small molecule 5 mg